flavonoids as therapeutic agents in alzheimer’s and parkinson’s diseases: a systematic review of preclinical evidences
Clicks: 176
ID: 220273
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
176 views
27 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #150 of 358 articles by views in journal of aoac international
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 358 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Alzheimer’s and Parkinson’s diseases are considered the most common neurodegenerative disorders, representing a major focus of neuroscience research to understanding the cellular alterations and pathophysiological mechanisms involved. Several natural products, including flavonoids, are considered able to cross the blood-brain barrier and are known for their central nervous system-related activity. Therefore, studies are being conducted with these chemical constituents to analyze their activities in slowing down the progression of neurodegenerative diseases. The present systematic review summarizes the pharmacological effects of flavonoids in animal models for Alzheimer’s and Parkinson’s diseases. A PRISMA model for systematic review was utilized for this search. The research was conducted in the following databases: PubMed, Web of Science, BIREME, and Science Direct. Based on the inclusion criteria, 31 articles were selected and discussed in this review. The studies listed revealed that the main targets of action for Alzheimer’s disease therapy were reduction of reactive oxygen species and amyloid beta-protein production, while for Parkinson’s disease reduction of the cellular oxidative potential and the activation of mechanisms of neuronal death. Results showed that a variety of flavonoids is being studied and can be promising for the development of new drugs to treat neurodegenerative diseases. Moreover, it was possible to verify that there is a lack of translational research and clinical evidence of these promising compounds.
| Reference Key |
teles2018oxidativeflavonoids
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Roxana Braga de Andrade Teles;Tâmara Coimbra Diniz;Tiago Coimbra Costa Pinto;Raimundo Gonçalves de Oliveira Júnior;Mariana Gama e Silva;Érica Martins de Lavor;Antonio Wilton Cavalcante Fernandes;Ana Paula de Oliveira;Fernanda Pires Rodrigues de Almeida Ribeiro;Amanda Alves Marcelino da Silva;Taisy Cinthia Ferro Cavalcante;Lucindo José Quintans Júnior;Jackson Roberto Guedes da Silva Almeida |
| Journal | journal of aoac international |
| Year | 2018 |
| DOI |
10.1155/2018/7043213
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.